

While attending the AMMI Canada – CACMID Annual Conference, you are cordially invited to attend an AMMI Canada / Bristol-Myers Squibb Canada Co-developed Accredited Learning Activity

Addressing Unmet Medical Needs in HCV Genotype 3

A C A S E - B A S E D A P P R O A C H

Saturday April 18, 2015 ♦ 07:15 – 08:45 (Registration and Breakfast: 07:15 – 07:45)

Tupper Room – PEI Convention Centre ♦ NOTE: Maximum of 50 participants (registration required)

This presentation will focus on new treatments available to genotype 3 treatment-naïve patients as well as difficult-to-treat patients (including those post-transplant). Using a case-based approach, our faculty will highlight the challenges specific to these patient types and discuss the optimal treatment options available in this rapidly changing clinical environment.

Learning Objectives

Following their participation in this program, participants will be able to:

- Identify treatment options available to various HCV patient populations
- Cite efficacy, safety, and tolerability data of different therapeutic options
- Recognize the expanding treatment armamentarium of HCV

Agenda

07:15 - 07:45	Registration and Breakfast	
07:45 - 07:50	Opening Remarks	<i>Dr. Duncan Webster</i>
07:50 - 08:35	Presentation	<i>Dr. Karen Doucette</i>
08:35 - 08:45	Question and Answer, Discussion, and Closing Remarks	<i>Dr. Duncan Webster</i>



Moderator

Duncan Webster, BSc, BA, MA, MD, FRCPC

Internist,
Infectious Disease Physician, Department of Medicine
Medical Microbiologist,
Department of Laboratory Medicine, Saint John Regional Hospital
Associate Professor,
Dalhousie University, Faculty of Medicine
Memorial University, Faculty of Medicine



Speaker

Karen Doucette, MD, MSc (Epi), FRCPC

Associate Professor,
Division of Infectious Diseases, Department of Medicine
University of Alberta

Click Here to Register: <http://fluidsurveys.com/s/2015WorkshopBMS/>

This program is made possible through educational support from



This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Bristol-Myers Squibb Canada and was planned to achieve scientific integrity, objectivity, and balance.

Under the guidance of the Rx&D Code of Ethical Practices this event is for healthcare professionals only.